year 17, Issue 2 (March - April 2023)                   Iran J Med Microbiol 2023, 17(2): 194-201 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Beheshti M, Neisi N, Parsanahad M, Rasti M, Pirmoradi R. Analysis of Sars-CoV-2 RBD Mutations in Khuzestan Province, Iran - A Retrospective Study, 2021. Iran J Med Microbiol 2023; 17 (2) :194-201
URL: http://ijmm.ir/article-1-1758-en.html
1- Department of Virology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2- Department of Virology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran , niloofarneisi@yahoo.com
3- Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Abstract:   (1000 Views)

Background and Aim: One of the main reasons for the ongoing pandemic is the substitutions in the Receptor binding domain (RBD), which is involved in binding to the ACE2 receptor.
Materials and Methods: Oro-nasopharyngeal swabs were collected from 41 confirmed patients between September 2020 and May 2021 to analyze the mutations of SARS-CoV-2 RBD in Khuzestan Province. Bi-Directional sequencing was used, and Mutation analysis was performed using multiple Bioinformatics tools.
Results: A total of 35 Single nucleotide polymorphisms (SNPs) were observed in 26 samples. Nonsynonymous substitutions occurred only in the receptor-binding motif (RBM), which accounted for 97% of the detected mutations. 37.14% of observed mutations were N501Y. L452R, T478K, and S477N accounted for 22.86%, 20%, and 11.43% of detected substitutions, respectively. Subsequently, the S477G and Y449N were identified in only one sample. The only synonymous substitution of this study was observed in C432 of one sample. It was found that December 2020 and May 2021 could be the probable prevalence times of the Alpha and Delta variants in Khuzestan, respectively. Also, in a December 2020 sample, a mutation was detected that was only seen in Epsilon among the Variants of interest and Variants of concern.
Conclusion: Our study showed the existence of some Omicron-related mutations before the emergence of this variant in Khuzestan Province, Iran. In addition, it strengthened the possibility of unconfirmed variants, such as Epsilon entering Iran. It also provided a reference for studies that need to be aware of the circulating variants in Iran.

Full-Text [PDF 665 kb]   (218 Downloads) |   |   Full-Text (HTML)  (199 Views)  
Type of Study: Original Research Article | Subject: Microbial Genetics
Received: 2022/07/24 | Accepted: 2023/01/28 | ePublished: 2023/03/30

References
1. Yavarian J, Shafiei-Jandaghi N-Z, Sadeghi K, Shatizadeh Malekshahi S, Salimi V, Nejati A, et al. First Cases of SARS-CoV-2 in Iran, 2020: Case Series Report. Iran J Public Health. 2020;49(8):1564-8. [DOI:10.18502/ijph.v49i8.3903] [PMID] [PMCID]
2. Worldometer. Reported Cases and Deaths by Country or Territory 2022 [Available from: https://www.worldometers.info/coronavirus/.
3. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020;79. [DOI:10.1016/j.meegid.2020.104212] [PMID] [PMCID]
4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. [DOI:10.1016/S0140-6736(20)30251-8] [PMID]
5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. [DOI:10.1056/NEJMoa2001017] [PMID] [PMCID]
6. Masters P, Perlman S. Coronaviridae In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams and Wilkins; 2013.
7. Abou-Hamdan M, Hamze K, Abdel Sater A, Akl H, El-Zein N, Dandache I, et al. Variant analysis of the first Lebanese SARS-CoV-2 isolates. Genomics. 2021;113(1 Pt 2):892-5. [DOI:10.1016/j.ygeno.2020.10.021] [PMID] [PMCID]
8. Forni D, Cagliani R, Clerici M, Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol. 2017;25(1):35-48. [DOI:10.1016/j.tim.2016.09.001] [PMID] [PMCID]
9. Yoshimoto FK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The protein journal. 2020;39(3):198-216. [DOI:10.1007/s10930-020-09901-4] [PMID] [PMCID]
10. Mohammadzadeh Rostami F, Nasr Esfahani BN, Ahadi AM, Shalibeik S. A Review of Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Iran J Med Microbiol. 2020;14(2):154-61. [DOI:10.30699/ijmm.14.2.154]
11. Shin HJ, Ku KB, Kim HS, Moon HW, Jeong GU, Hwang I, et al. Receptor-binding domain of SARS-CoV-2 spike protein efficiently inhibits SARS-CoV-2 infection and attachment to mouse lung. Int J Biol Sci. 2021;17(14):3786-94. [DOI:10.7150/ijbs.61320] [PMID] [PMCID]
12. Duffy S. Why are RNA virus mutation rates so damn high? PLOS Biol. 2018;16(8):e3000003. [DOI:10.1371/journal.pbio.3000003] [PMID] [PMCID]
13. Callaway E. The coronavirus is mutating--does it matter? Nature. 2020;585(7824):174-8. [DOI:10.1038/d41586-020-02544-6] [PMID]
14. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KH, Dingens AS, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182(5):1295-310. e20. [DOI:10.1016/j.cell.2020.08.012] [PMID] [PMCID]
15. Chakraborty C, Bhattacharya M, Sharma AR. Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity. Rev Med Virol. 2021;32(2):e2270. [DOI:10.1002/rmv.2270] [PMCID]
16. Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27(8):1109-17. [DOI:10.1016/j.cmi.2021.05.022] [PMID] [PMCID]
17. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell host & microbe. 2021;29(1):44-57. e9. [DOI:10.1016/j.chom.2020.11.007] [PMID] [PMCID]
18. Khan A, Zia T, Suleman M, Khan T, Ali SS, Abbasi AA, et al. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data. J Cell Physiol. 2021;236(10):7045-57. [DOI:10.1002/jcp.30367] [PMID] [PMCID]
19. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021. [DOI:10.1016/j.cell.2021.04.025] [PMID] [PMCID]
20. Sender R, Bar-On YM, Gleizer S, Bernshtein B, Flamholz A, Phillips R, et al. The total number and mass of SARS-CoV-2 virions. Proc Natl Acad Sci. 2021;118(25):e2024815118. [DOI:10.1073/pnas.2024815118] [PMID] [PMCID]
21. Laha S, Chakraborty J, Das S, Manna SK, Biswas S, Chatterjee R. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect Genet Evol. 2020;85:104445. [DOI:10.1016/j.meegid.2020.104445] [PMID] [PMCID]
22. Popa A, Genger JW, Nicholson MD, Penz T, Schmid D, Aberle SW, et al. Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Science translational medicine. 2020;12(573).
23. Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ (Clinical research ed). 2021;372. [DOI:10.1136/bmj.n296] [PMID]
24. Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021(2021):01. [DOI:10.1101/2021.01.25.427948]
25. Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371(6531):850-4. [DOI:10.1126/science.abf9302] [PMID] [PMCID]
26. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020:2020.12.21.20248640. [DOI:10.1101/2020.12.21.20248640]
27. Mwenda M, Saasa N, Sinyange N, Busby G, Chipimo PJ, Hendry J, et al. Detection of B. 1.351 SARS-CoV-2 variant strain-Zambia, december 2020. Morb Mortal Wkly Rep. 2021;70(8):280. [DOI:10.15585/mmwr.mm7008e2] [PMID] [PMCID]
28. Nonaka CKV, Gräf T, Barcia CAdL, Costa VF, de Oliveira JL, Passos RdH, et al. SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021. Int J Infect Dis. 2021;111:47-54. [DOI:10.1016/j.ijid.2021.08.003] [PMID] [PMCID]
29. Francisco RDS, Jr., Benites LF, Lamarca AP, de Almeida LGP, Hansen AW, Gularte JS, et al. Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil. Virus research. 2021;296:198345. [DOI:10.1016/j.virusres.2021.198345] [PMID] [PMCID]
30. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med. 2021;27(7):1131-3. [DOI:10.1038/s41591-021-01397-4] [PMID]
31. Despres HW, Mills MG, Shirley DJ, Schmidt MM, Huang M-L, Jerome KR, et al. Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants. medRxiv. 2021:2021.09.07.21263229. [DOI:10.1101/2021.09.07.21263229]
32. Tchesnokova V, Kulasekara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al. Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants. J Clini Microbiol. 2021;59(11):e00921-21. [DOI:10.1128/JCM.00921-21] [PMID] [PMCID]
33. Gowrisankar A, Priyanka TMC, Banerjee S. Omicron: a mysterious variant of concern. Eur Phys J Plus. 2022;137(1):100-. [DOI:10.1140/epjp/s13360-021-02321-y] [PMID] [PMCID]
34. Karimdadi Sariani O, Sadeghi Dousari A, Taati Moghadam M. Possible Psychological Consequences in Public of Omicron Variant (B. 1.1. 529) of SARS-CoV-2 Identification in Iran. Iran J Med Microbiol. 2022;16(5):485-7. [DOI:10.30699/ijmm.16.5.485]
35. Sathipati SY, Shukla SK, Ho S-Y. Tracking the amino acid changes of spike proteins across diverse host species of severe acute respiratory syndrome coronavirus 2. Iscience. 2022;25(1):103560. [DOI:10.1016/j.isci.2021.103560] [PMID] [PMCID]
36. Jiang Y, Wu Q, Song P, You C. The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. Front Med. 2022;8:806641-. [DOI:10.3389/fmed.2021.806641] [PMID] [PMCID]
37. Islam MR, Hossain MJ. Detection of SARS-CoV-2 Omicron (B.1.1.529) variant has created panic among the people across the world: What should we do right now? J Med Virol. 2021;94(5):1768-9. [DOI:10.1002/jmv.27546] [PMID]
38. Farkas C, Mella A, Haigh JJ. Large-scale population analysis of SARS-CoV-2 whole genome sequences reveals host-mediated viral evolution with emergence of mutations in the viral Spike protein associated with elevated mortality rates. medRxiv. 2021:2020.10.23.20218511. [DOI:10.1101/2020.10.23.20218511]
39. Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature. 2021;595(7869):707-12. [DOI:10.1038/s41586-021-03677-y] [PMID]
40. Singh A, Steinkellner G, Köchl K, Gruber K, Gruber CC. Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2. Sci Rep. 2021;11(1):4320. [DOI:10.1038/s41598-021-83761-5] [PMID] [PMCID]
41. Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020;370(6519):950-7. [DOI:10.1126/science.abe3354] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc